Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Natalizumab Plus Steroids for High Risk Acute GVHD
NCT02133924Phase 2Completed
- Start
- Aug 2016
- Primary completion
- Dec 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of natalizumab in Acute Graft-Versus-Host Disease (aGvHD). Started Aug 2016; status: completed.
02
Drugs
natalizumab
03
Conditions
Acute Graft-Versus-Host Disease (aGvHD)
Beyond the preview
Go deeper on NCT02133924.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02133924.